Campbell University School of Pharmacy and Health Sciences, Durham, NC, USA.
Ann Pharmacother. 2011 May;45(5):649-57. doi: 10.1345/aph.1P575. Epub 2011 Apr 26.
To evaluate literature reporting on the role of norepinephrine in alcohol withdrawal and to determine the safety and efficacy of α(2)-agonists in reducing symptoms of this severe condition.
Articles evaluating the efficacy and safety of the α(2)-agonists clonidine and dexmedetomidine were identified from an English-language MEDLINE search (1966-December 2010). Key words included alcohol withdrawal, delirium tremens, clonidine, dexmedetomidine, α(2)-agonist, norepinephrine, and sympathetic overdrive.
Studies that focused on the safety and efficacy of clonidine and dexmedetomidine in both animals and humans were selected.
The noradrenergic system, specifically sympathetic overdrive during alcohol withdrawal, may play an important role in withdrawal symptom development. Symptoms of sympathetic overdrive include anxiety, agitation, elevated blood pressure, tachycardia, and tremor. Therefore, α(2)-agonists, which decrease norepinephine release, may have a role in reducing alcohol withdrawal symptoms. The majority of controlled animal and human studies evaluated clonidine, but the most recent literature is from case reports on dexmedetomidine. The literature reviewed here demonstrate that these 2 α(2)-agonists safely and effectively reduce symptoms of sympathetic overdrive and concomitant medication use. Dexmedetomidine may offer an advantage over current sedative medications used in the intensive care unit, such as not requiring intubation with its use, and therefore further study is needed to fully elicit its benefit in alcohol withdrawal.
Clonidine and dexmedetomidine may provide additional benefit in managing alcohol withdrawal by offering a different mechanism of action for targeting withdrawal symptoms. Based on literature reviewed here, the primary role for clonidine and dexmedetomidine is as adjunctive treatment to benzodiazepines, the standard of care in alcohol withdrawal.
评估去甲肾上腺素在酒精戒断中的作用,并确定 α(2)-激动剂在减轻这种严重疾病症状方面的安全性和有效性。
从英语 MEDLINE 搜索(1966 年至 2010 年 12 月)中确定了评估 α(2)-激动剂可乐定和右美托咪定疗效和安全性的文章。关键词包括酒精戒断、震颤谵妄、可乐定、右美托咪定、α(2)-激动剂、去甲肾上腺素和交感神经兴奋过度。
选择了专注于可乐定和右美托咪定在动物和人类中的安全性和有效性的研究。
去甲肾上腺素能系统,特别是酒精戒断期间的交感神经兴奋过度,可能在戒断症状的发展中起重要作用。交感神经兴奋过度的症状包括焦虑、激动、血压升高、心动过速和震颤。因此,降低去甲肾上腺素释放的 α(2)-激动剂可能在减轻酒精戒断症状方面发挥作用。大多数对照动物和人类研究评估了可乐定,但最近的文献来自右美托咪定的病例报告。这里回顾的文献表明,这两种 α(2)-激动剂安全有效地减轻了交感神经兴奋过度的症状,同时减少了伴随药物的使用。右美托咪定可能比目前在重症监护病房中使用的镇静药物具有优势,因为在使用时不需要插管,因此需要进一步研究以充分阐明其在酒精戒断中的益处。
可乐定和右美托咪定通过提供针对戒断症状的不同作用机制,可能为治疗酒精戒断提供额外的益处。基于这里回顾的文献,可乐定和右美托咪定的主要作用是作为苯二氮䓬类药物的辅助治疗,苯二氮䓬类药物是酒精戒断的标准治疗方法。